NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. The company also has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone46-4-627-562-20
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7
Next Earnings Date11/28/2019 (Estimated)
OptionableNot Optionable
NeuroVive Pharmaceutical (OTCMKTS:NEVPF) Frequently Asked Questions
What is NeuroVive Pharmaceutical's stock symbol?
NeuroVive Pharmaceutical trades on the OTCMKTS under the ticker symbol "NEVPF."
How were NeuroVive Pharmaceutical's earnings last quarter?
NeuroVive Pharmaceutical AB (OTCMKTS:NEVPF) released its earnings results on Wednesday, August, 21st. The company reported ($0.02) earnings per share (EPS) for the quarter. The company earned $0.01 million during the quarter. View NeuroVive Pharmaceutical's Earnings History.
When is NeuroVive Pharmaceutical's next earnings date?
Has NeuroVive Pharmaceutical been receiving favorable news coverage?
News coverage about NEVPF stock has been trending somewhat positive on Wednesday, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeuroVive Pharmaceutical earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for NeuroVive Pharmaceutical.
Who are some of NeuroVive Pharmaceutical's key competitors?
Some companies that are related to NeuroVive Pharmaceutical include Provectus Biopharmaceuticals (PVCT), ContraFect (CFRX), Intec Pharma (NTEC), Ceapro (CRPOF), Acerus Pharmaceuticals (TRLPF), Sierra Oncology (SRRA), ProPhase Labs (PRPH), AEterna Zentaris (AEZS), BIOLINERX LTD/S (BLRX), Aerpio Pharmaceuticals (ARPO), Seelos Therapeutics (SEEL), RegeneRx Biopharmaceuticals (RGRX), Cassava Sciences (SAVA), Kazia Therapeutics (KZIA) and Aytu Bioscience (AYTU).
What other stocks do shareholders of NeuroVive Pharmaceutical own?
Who are NeuroVive Pharmaceutical's key executives?
NeuroVive Pharmaceutical's management team includes the folowing people:
- Mr. Erik Kinnmann M.D., Ph.D., M.B.A., Assoc. Prof., Chief Exec. Officer (Age 61)
- Ms. Catharina Jz Johansson, CFO & VP of Investor Relations (Age 52)
- Dr. Eskil Elmér, Chief Scientific Officer & VP of Discovery (Age 49)
- Daniel Schale, Director of Communications
- Dr. Magnus Hansson, Chief Medical Officer and VP of Preclinical & Clinical Devel. (Age 43)
How do I buy shares of NeuroVive Pharmaceutical?
Shares of NEVPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is NeuroVive Pharmaceutical's stock price today?
One share of NEVPF stock can currently be purchased for approximately $0.18.
How big of a company is NeuroVive Pharmaceutical?
NeuroVive Pharmaceutical has a market capitalization of $9.63 million. The company earns $-7,870,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. NeuroVive Pharmaceutical employs 7 workers across the globe.View Additional Information About NeuroVive Pharmaceutical.
What is NeuroVive Pharmaceutical's official website?
How can I contact NeuroVive Pharmaceutical?
NeuroVive Pharmaceutical's mailing address is MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381. The company can be reached via phone at 46-4-627-562-20 or via email at [email protected]
MarketBeat Community Rating for NeuroVive Pharmaceutical (OTCMKTS NEVPF)
MarketBeat's community ratings are surveys of what our community members think about NeuroVive Pharmaceutical and other stocks. Vote "Outperform" if you believe NEVPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEVPF will underperform the S&P 500 over the long term. You may vote once every thirty days.
